Table 3 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Key Points

• Over 20% of patients experienced treatment-emergent adverse events during the trial.
• The safety analysis involved 41 patients receiving the combination therapy with hormone receptor-positive, HER2-negative advanced breast cancer.
• Combination therapy with gedatolisib, palbociclib, and letrozole may offer a novel treatment strategy.
• Findings may support changes in therapy approaches for patients with advanced breast cancer.